Dr. John C. Ruckdeschel is no longer practicing medicine at the University of Mississippi Medical Center Cancer Institute. Mesothelioma patients can seek specialized treatment from other doctors in Mississippi or nearby states.
01. Doctor Overview
Doctor Overview
Dr. John C. Ruckdeschel earned his medical degree from Albany Medical College before completing a Medical Oncology Fellowship at the National Cancer Institute. His focus on lung cancer and thoracic malignancies built an impressive career in the space with more than 150 peer-reviewed studies to his name. Dr. Ruckdeschel is no longer accepting patients and is now pursuing other endeavors.
Dr. Ruckdeschel had extensive experience running and optimizing comprehensive cancer treatment centers. He directed or managed a long list of prestigious centers including the Barbara Ann Karmanos Cancer Center in Detroit, the Moffitt Cancer Center in Tampa and the University of Mississippi Cancer Center and Research Institute. In each organization, he strengthened the focus on high-performing interdisciplinary patient-care teams.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Oncology
Other Interests & Specialties: Neuro-oncology, general oncology, hematologic oncology, thoracic cancer, lung cancers and mesothelioma.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine and Medical Oncology, St. George Award from the American Cancer Society
Education & Experience:
- Residency for Internal Medicine at Beth Israel Deaconess Medical Center
- Fellowship for Medical Oncology at National Cancer Institute
- Fellowship at Baltimore Cancer Research Center
- Internship for Internal Medicine at Johns Hopkins University
- Medical Degree from Albany Medical College
03. Publications
Publications
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemotherapy and Pharmacology. August 2010;66(3):455-466.
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. September 2014;85(3):429-434. doi: 10.1016/j.lungcan.2014.06.008
